The critical role of the endogenous immune compartment after CAR T cell therapy in recurrent GBM.

Endogenous immune responses, especially natural killer cell expansion, are crucial for successful CAR T cell therapy in recurrent GBM, with responders showing significant immune remodeling.

• Why it matters: Understanding the immune factors that influence treatment outcomes is vital because glioblastoma has limited options after recurrence, and current therapies often fail to prevent relapse.
• What they did: The study analyzed cerebrospinal fluid and tumor samples from patients treated with CAR T cells, focusing on immune cell dynamics and identifying differences between responders and non-responders.
• The result: Findings show that responders exhibit natural killer cell expansion, while non-responders have increased regulatory T cells and immunosuppressive myeloid cells, highlighting the potential of immune modulation to enhance therapy.